First Bellwether Trial Begins Against Reckitt Benckiser Over Enfamil Safety

Key Facts

In a move that puts the legal liabilities of consumer goods giants under intense scrutiny, the first bellwether trial against Mead Johnson, a subsidiary of Reckitt Benckiser, commenced today in the US District Court for the Northern District of Illinois. The litigation centers on allegations that Enfamil infant formula is linked to necrotizing enterocolitis (NEC), a severe intestinal disease, in premature infants. According to reports, the trial aims to determine whether the company failed to provide adequate warning labels regarding the risks associated with its cow's milk-based formula.

These legal proceedings emerge as investors weigh the potential for significant settlements or damages that often accompany multidistrict litigation. Per market data, shares of Reckitt Benckiser (RKT.L) stood at 5114 pence at the close of August 14, 2026, having traded between a high of 5154 and a low of 5088 during that session. The outcome of this bellwether case is critical, as it serves as a signal for the potential liability the firm faces across numerous similar claims.

Looking ahead, market participants will closely monitor developments from the Illinois court for any impact on the stock, which was priced at 5114 pence (close August 14, 2026). While the upcoming economic calendar does not list immediate sector-specific catalysts, broader sentiment in the consumer goods space remains sensitive to the progression of high-stakes legal challenges such as this one.